SCHEMBL23934206

SCHEMBL23934206

COc1ccc(C(=O)Nc2ccc(NC(=O)c3cccc(OC)c3OC)c3c2C(=O)N(C)C3=O)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 3/20 0.55
GAA P10253 2/20 0.55
CHEK1 O14757 1/20 0.53
PIM1 P11309 1/20 0.53
MAPK8 P45983 1/20 0.53
CLK4 Q9HAZ1 1/20 0.53
KMT2A Q03164 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MAPT P10636 2/20 0.50
LMNA P02545 2/20 0.50
POLB P06746 2/20 0.50
MEN1 O00255 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
PDE4D Q08499 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934278 0.74 MAPT (0.54) ALDH1A1KDM4EKMT2ANPC1RAB9A
SCHEMBL29603751 0.73 GAA (0.70) ALDH1A1KDM4EGAAKMT2ANPC1
SCHEMBL13576585 0.71 PDE4D (0.76) ALDH1A1KDM4ECHEK1PIM1MAPK8
SCHEMBL11764286 0.71 CYP1A2 (0.64) ALDH1A1KDM4EGAAKMT2ANPC1
SCHEMBL15233675 0.71 CYP1A2 (0.59) ALDH1A1KDM4ECHEK1PIM1MAPK8
SCHEMBL11244161 0.71 PDE4D (0.81) ALDH1A1KDM4ECHEK1PIM1MAPK8
SCHEMBL29603459 0.70 ALDH1A1 (0.67) ALDH1A1KDM4EGAAKMT2ANPC1
SCHEMBL22833906 0.70 ALDH1A1 (0.67) ALDH1A1KDM4EGAAKMT2ANPC1
SCHEMBL6476440 0.70 MAPK14 (0.66) ALDH1A1CHEK1PIM1MAPK8CLK4
SCHEMBL266327 0.70 CHEK1 (0.80) ALDH1A1KDM4EGAACHEK1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 ALDH1A1 4396/4885KDM4E 1367/4885GAA 3143/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 ALDH1A1 4396/4885KDM4E 1367/4885GAA 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.